Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -214 Thousand USD | -117.53% |
| 2022 | 1.22 Million USD | 142.41% |
| 2021 | -2.87 Million USD | 89.81% |
| 2020 | -28.26 Million USD | -542.78% |
| 2019 | -4.39 Million CAD | 9.98% |
| 2018 | -4.88 Million CAD | -81.14% |
| 2017 | -2.69 Million CAD | -96.32% |
| 2016 | -1.37 Million CAD | 22.45% |
| 2015 | -1.77 Million CAD | 44.95% |
| 2014 | -3.21 Million CAD | 35.63% |
| 2013 | -4.99 Million CAD | -3242.34% |
| 2012 | -149.56 Thousand CAD | -109759.78% |
| 2011 | -136.14 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.95 Million USD | 156.82% |
| 2023 Q4 | 762 Thousand USD | 242.7% |
| 2023 Q3 | -534 Thousand USD | 51.14% |
| 2023 Q2 | -1.09 Million USD | -267.9% |
| 2023 Q1 | 651 Thousand USD | -90.5% |
| 2023 FY | -214 Thousand USD | -117.53% |
| 2022 Q1 | -1.39 Million USD | 73.56% |
| 2022 Q2 | -2.73 Million USD | -95.28% |
| 2022 Q3 | -1.5 Million USD | 44.8% |
| 2022 Q4 | 6.85 Million USD | 554.94% |
| 2022 FY | 1.22 Million USD | 142.41% |
| 2021 FY | -2.87 Million USD | 89.81% |
| 2021 Q2 | 10.14 Million USD | 254.02% |
| 2021 Q3 | -1.15 Million USD | -111.34% |
| 2021 Q1 | -6.58 Million USD | 31.1% |
| 2021 Q4 | -5.28 Million USD | -359.74% |
| 2020 Q3 | -13.38 Million CAD | -783.79% |
| 2020 Q4 | -9.55 Million USD | 28.57% |
| 2020 Q2 | -1.51 Million CAD | 56.53% |
| 2020 Q1 | -3.48 Million CAD | -181.8% |
| 2020 FY | -28.26 Million USD | -542.78% |
| 2019 Q1 | -1.64 Million CAD | -120.03% |
| 2019 Q3 | -2.01 Million CAD | -505.37% |
| 2019 Q2 | 497.05 Thousand CAD | 130.29% |
| 2019 FY | -4.39 Million CAD | 9.98% |
| 2019 Q4 | -1.23 Million CAD | 38.65% |
| 2018 Q1 | -526.22 Thousand CAD | 28.89% |
| 2018 Q4 | -745.89 Thousand CAD | 23.55% |
| 2018 FY | -4.88 Million CAD | -81.14% |
| 2018 Q3 | -975.63 Thousand CAD | 65.14% |
| 2018 Q2 | -2.79 Million CAD | -431.92% |
| 2017 Q1 | -859.57 Thousand CAD | 17.65% |
| 2017 Q3 | -800.07 Thousand CAD | -194.84% |
| 2017 Q4 | -739.99 Thousand CAD | 7.51% |
| 2017 FY | -2.69 Million CAD | -96.32% |
| 2017 Q2 | -271.36 Thousand CAD | 68.43% |
| 2016 Q2 | -637.62 Thousand CAD | -157.18% |
| 2016 FY | -1.37 Million CAD | 22.45% |
| 2016 Q1 | 1.11 Million CAD | 12.25% |
| 2016 Q4 | -1.04 Million CAD | -33.91% |
| 2016 Q3 | -779.51 Thousand CAD | -22.25% |
| 2015 FY | -1.77 Million CAD | 44.95% |
| 2015 Q4 | 993.43 Thousand CAD | 207.03% |
| 2015 Q3 | -928.17 Thousand CAD | -30.61% |
| 2015 Q2 | -710.62 Thousand CAD | 44.68% |
| 2015 Q1 | -1.28 Million CAD | -142.56% |
| 2014 Q1 | -761.75 Thousand CAD | 0.0% |
| 2014 FY | -3.21 Million CAD | 35.63% |
| 2014 Q4 | -529.62 Thousand CAD | 45.16% |
| 2014 Q2 | -1.06 Million CAD | -39.6% |
| 2014 Q3 | -965.78 Thousand CAD | 9.18% |
| 2013 Q3 | -1.59 Million CAD | -9608.38% |
| 2013 FY | -4.99 Million CAD | -3242.34% |
| 2013 Q1 | -1995.89 CAD | 79.78% |
| 2013 Q2 | -16.47 Thousand CAD | -725.48% |
| 2012 Q4 | -9870.76 CAD | 98.51% |
| 2012 Q1 | -29.75 Thousand CAD | 68.51% |
| 2012 Q3 | -663.38 Thousand CAD | -27732.03% |
| 2012 FY | -149.56 Thousand CAD | -109759.78% |
| 2012 Q2 | -2383.54 CAD | 91.99% |
| 2011 Q4 | -94.47 Thousand CAD | 0.0% |
| 2011 FY | -136.14 CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -69.32 Million CAD | 99.691% |
| Avicanna Inc. | -8.74 Million CAD | 97.552% |
| Avant Brands Inc. | -5.07 Million CAD | 95.779% |
| Cardiol Therapeutics Inc. | -28.12 Million CAD | 99.239% |
| Crescita Therapeutics Inc. | -1.98 Million CAD | 89.225% |
| Knight Therapeutics Inc. | -16.83 Million CAD | 98.729% |
| MediPharm Labs Corp. | -13.08 Million CAD | 98.364% |
| OrganiGram Holdings Inc. | -229.47 Million CAD | 99.907% |
| Canopy Growth Corporation | -657.26 Million CAD | 99.967% |
| Willow Biosciences Inc. | -13.02 Million CAD | 98.358% |
| Auxly Cannabis Group Inc. | -44.51 Million CAD | 99.519% |